Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tests could help spot hidden blood disorder in seniors

NCT ID NCT01648556

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 37 adults over age 60 with unexplained low platelet counts to see if certain tests could predict immune thrombocytopenic purpura (ITP). Participants had blood tests, bone marrow biopsies, and a short course of the steroid prednisone. The goal was to find which tests best point to ITP, helping doctors avoid unnecessary procedures and start the right treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prednisone
What this could lead to
If successful, this could help doctors better diagnose immune thrombocytopenia in older adults, leading to more targeted treatment.
What could go wrong
This is a small, completed study with only 37 participants. The results may not apply to all patients, and the tests studied might not be reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

37 people

The number who actually took part.

Started

Jan 2013

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Rate of platelet \< 100 G/l for less than 12 months , * age = ou \> 60 years, * haemoglobin \> ou = 12 g / dl at the woman, \> ou = 13 g/dl at the man, * polymorphonuclear neutrophil \> ou = 1.7 G/l, * monocytes \< ou= 1 G/l, * lymphocytes \< ou = à 4 G/l, * VGM \< 100 fL, blood film normal, * informed consent, * expectation of life \> 6 months Exclusion Criteria: * hepatomegaly, * splenomegaly, * hepatic abnormality, * blood coagulation abnormality, * antecedent of auto-immune disease, * drug thrombopenia, * HIV, VHB or VHC positive, * antecedent of malicious tumor in the 5 years before inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenic purpura are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Purpura thrombopenic

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.